Skip to content
ClinCalc Pro
Menu
Topical otic spray (steroid + acidifier + aminoglycoside)

Dexamethasone with glacial acetic acid and neomycin sulfate

Brand names: Otomize

Used in: Meningitis & Encephalitis

A compound ear preparation (e.g. Otomize spray) combining the corticosteroid dexamethasone, the acidifying agent glacial acetic acid and the aminoglycoside antibiotic neomycin sulfate, used topically for otitis externa.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Dexamethasone reduces local inflammation and oedema, glacial acetic acid lowers ear-canal pH to inhibit microbial growth, and neomycin provides bactericidal aminoglycoside cover against common otitis externa pathogens.

Prescribing in practice

  • Avoid in patients with a perforated tympanic membrane because topical aminoglycosides such as neomycin carry a risk of ototoxicity when they reach the middle ear.
  • Neomycin is a recognised contact sensitiser, so discontinue if signs of local hypersensitivity or worsening dermatitis develop.
  • Reserve for short courses and review if the condition fails to settle, to limit sensitisation and superinfection with resistant organisms or fungi.

Monitoring

Monitor clinically for symptom resolution and for any new hearing disturbance, tinnitus or local hypersensitivity during treatment.

Counselling the patient

  • Use only in the affected ear and complete the recommended short course rather than continuing indefinitely.
  • Stop and seek advice if you develop dizziness, ringing in the ears, hearing changes or a rash.
  • Tell the clinician if you think your eardrum may be perforated.

Evidence & guidelines

Topical antibiotic-corticosteroid drops are an established first-line treatment for acute otitis externa, consistent with NICE and UK ENT guidance.

Reference: NICE CKS Otitis externa; ENT UK; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.